Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 6 Colorectal Neoplasms 6 Uterine Cervical Neoplasms 4 Breast Neoplasms 3 Uterine Cervical Dysplasia 2 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Lung Neoplasms 2 Gastrointestinal Neoplasms 2 Warts 1 Urinary Bladder Neoplasms 1 Tinea 1 Skin Neoplasms 1 Retinoblastoma 1 Pulmonary Atelectasis 1 Postoperative Complications 1 Pneumonia 1 Papillomavirus Infections 1 Oncology Problem 1 Nevus 1 Multiple Endocrine Neoplasia Type 1 1 Molluscum Contagiosum 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Kidney Failure, Chronic 1 Keratosis, Actinic 1 Intestinal Neoplasms 1 Impetigo 1 Herpes Zoster 1 Heart Diseases 1

Interventions

LY3295668 erbumine 2 Everolimus 2 ziprasidone 1 enzalutamide 1 clevidipine 1 Zolpidem 1 Warfarin 1 Vecuronium Bromide 1 Vancomycin 1 Tranexamic Acid 1 Tobramycin 1 Spironolactone 1 Sirolimus 1 Sevoflurane 1 Sevelamer 1 Saline Solution 1 Rocuronium 1 Propofol 1 Piperacillin, Tazobactam Drug Combination 1 Pentobarbital 1 Oxycodone 1 Nitrous Oxide 1 Nifedipine 1 Nafcillin 1 Molindone 1 Midazolam 1 Methylprednisolone 1 Mass Screening 1 Lurasidone Hydrochloride 1 Lidocaine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Epilepsy × Mass Screening × Clear all

NCT00152659 2023-04-26

Developing Criteria for Cortical Resections

University of Chicago

Epilepsy, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡